Physicians' Academy for Cardiovascular Education
Click here to watch this as part of CME accredited course

How are the guidelines for progressive CAD guiding us in clinical practice?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser - Online CME

Click here to watch this as part of CME accredited course

Video navigation menu

  • Are current treatment options for high CV risk patients adequately reflected in the guidelines? 00:30
  • Will the guidelines address new therapeutic areas? 02:39
  • Is the evidence for PCSK9 inhibitors enough? 04:04

Educational information

This video was recorded during an expert meeting among cardiologists and internists, focussing on the topic of 'LDL-c & PCSK9 inhibition in high CV risk patients - Balancing Science, Guidelines and Daily Cardiology Practice'.

The objectives of the meeting were to:

Other topics covered in this series

Other lectures part of this educational series are:

Faculty

Prof. John J.P. Kastelein, MD, internist, Professor of Medicine, Department of Vascular Medicine; Strategic Chair of Genetics of Cardiovascular Disease at the Amsterdam University Medical Centers (AUMC) of the University of Amsterdam, The Netherlands

Prof. Ulf Landmesser, MD, cardiologist, Charité-Universitätsmedizin Berlin, Germany

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Funding for the Expert Meeting was provided by an unrestricted educational grant from Amgen. The sponsor did not attend and influence the video recording.

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.

Share this page with your colleagues and friends: